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Abstract 
Mast cells are an exceptionally rich source of prostaglandin D2 (PGD2). PGD2 is pro-
inflammatory and can cause bronchoconstriction. The enzyme cyclooxygenase (COX) 
is central to the generation of prostanoids such as PGD2.  Non-steroidal anti-
inflammatory drugs (NSAIDs) inhibit COX. COX exists as two isoforms, COX-1 and 
COX-2.  The principal aim of this study was to establish whether COX-1 and/or 
COX-2 mediates PGD2 generation from human lung mast cells.  Mast cells were 
isolated from human lung tissue and purified by flotation over Percoll and 
immunomagnetic bead separations. The cells were activated with anti-IgE or Stem 
Cell Factor (SCF).  The generation of PGD2 was determined by ELISA. The effects of 
NSAIDs (aspirin, ibuprofen, diclofenac, naproxen, indomethacin), COX-1 selective 
(FR122047), and COX-2 selective (celecoxib) inhibitors on PGD2 generation were 
determined. The expression of COX-1 and COX-2 in mast cells was determined by 
Western blotting.  All the NSAIDs tested abrogated stimulated PGD2 generation from 
mast cells except aspirin which was only weakly effective. FR122047 was an 
effective inhibitor of PGD2 generation (EC50 ~25 nM) from mast cells whereas 
celecoxib was ineffective. Immunoblotting indicated that COX-1 was strongly 
expressed in all mast cell preparations while COX-2 expression was weak. No 
induction of COX-2 was observed following activation of mast cells. These findings 
indicate that COX-1 is the principal isoform involved in generating PGD2 from 
human lung mast cells. These studies provide insight into the potential behaviour of 
NSAIDs in the context of respiratory diseases.  
 
Keywords:  
mast cells, cyclooxygenase, NSAIDs, aspirin, prostaglandin D2  
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1. Introduction 
Mast cells are a very rich source of the prostanoid, PGD2 (Lewis et al., 1982). Since 
very few other cells have the capacity to produce PGD2, the presence of PGD2 or its 
metabolites is likely to be indicative of mast cell activation (Bochenek et al., 2004; 
Dahlén et al., 2004). PGD2 mediates bronchoconstriction and is largely pro-
inflammatory (Beasley et al., 1987; Matsuoaka et al., 2000).  Together with other 
mast cell derived mediators such as histamine and cysteinyl-leukotrienes (cys-LTs), 
PGD2 contributes to allergic type reactions (Bingham and Austen, 2000; Bradding et 
al., 2006).  While the recognition that human lung mast cells produce PGD2 has been 
acknowledged for some time, the pathway leading to PGD2 generation in these cells 
has not been clearly delineated. 
The enzyme cyclooxygenase (COX) is central to the generation of prostanoids 
(Rouzer and Marnett, 2009). COX converts arachidonic acid to a highly labile 
intermediate, PGH2.  Specific synthases then convert PGH2 into prostanoids. Whereas 
COX is found widely, synthases tend to show more restricted distribution (Ueno et 
al., 2005). Other than PGD2, important prostanoids include PGE2, PGFĮ, PGI2, and 
TXA2 (Woodward et al., 2011). These display varying profiles of activity.  For 
example, PGE2 is known to inhibit acid secretion from parietal cells in the gut and 
also appears to be important in mediating inflammation and sensitizing sensory 
neurones to pain (Tilley et al., 2001; Peskar et al., 2003; Woodward et al., 2011). 
Non-steroidal anti-inflammatory drugs (NSAIDs), such as aspirin and 
ibuprofen, target COX and, by attenuating prostanoid generation, are useful for the 
treatment of certain types of inflammation and pain (Cryer and Feldman, 1998).  COX 
is known to exist as two isoforms COX-1 and COX-2.  COX-1 is recognised as the 
isoform that is expressed constitutively whereas COX-2 is thought to be the form that 
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is induced during inflammation (Mitchell et al., 1994; Cryer and Feldman, 1998; 
Chan et al., 1999; Warner et al., 1999).  However, constitutive expression of COX-2 
may also occur in certain tissues indicating that this isoform cannot solely be 
considered an inducible form of the enzyme (Kirkby et al., 2016).  Aspirin and 
ibuprofen are somewhat non-selective drugs and affect both isoforms of COX 
(Mitchell et al., 1994; Cryer and Feldman, 1998; Chan et al., 1999; Warner et al., 
1999).  Any anti-inflammatory benefit of non-selective NSAIDs may therefore be 
accompanied by non-target effects including inhibition of COX-1 in the gut, leading 
to a reduction in the production of PGE, increased acid secretion and potential 
gastropathy (Warner et al., 1999).  Since many NSAIDs show limited selectivity for 
either COX-1 or COX-2, this has led to the development of COX-2 selective drugs 
such as celecoxib that are less likely to target COX-1 and are gut-sparing (Chan et al., 
1999; Warner et al., 1999; Fitzgerald and Patrono, 2001).  
 Despite the undoubted value of NSAIDs in the treatment of certain types of 
inflammation and moderate pain, the use of aspirin and related compounds is largely 
contraindicated in individuals with asthma and respiratory diseases. This is because 
aspirin can induce exacerbations in a sizeable proportion of asthmatics (Kowalski et 
al., 2011). The mechanism behind this underlying susceptibility to aspirin and related 
drugs has not been elucidated but aspirin intolerance has been linked to increased 
production of both cys-LTs and PGD2 2¶6XOOLYDQHWDO&DKLOOHWDO.  
The production of PGD2 suggests that mast cells are central to the process.  While an 
expectation would be that NSAIDs are likely to inhibit PGD2 generation from human 
lung mast cells, there are suggestions that aspirin might activate mast cells by 
mechanisms that are not clearly understood (Steinke et al., 2014).  
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To date, no systematic evaluation of the effects of NSAIDs on human lung 
mast cells has been performed.  The present study aims to redress this.  Studies in 
rodent cell systems and in cultured human mast cells suggest that both COX-1 and 
COX-2 may contribute to PGD2 production (Murakami et al., 1995; Reddy et al., 
1997; Obata et al., 1999).  However, it is well recognised that mast cells isolated from 
different species and different sites from the same species display a great deal of 
heterogeneity (Pearce, 1983; Lowman et al., 1988).  The principal aim of this study, 
therefore, was to identify which isoform(s) of COX mediates PGD2 generation from 
human lung mast cells. The findings of this study may help to explain the actions and 
behaviour of NSAIDs in the context of respiratory disease.  
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2. Materials & Methods  
2.1 Buffers   
Phosphate buffered saline (PBS) was employed in these studies.  PBS contained 
(mM): NaCl 137; Na2HPO4.7H2O 8; KCl 2.7; KH2PO4 1.5.  +PBS was PBS 
supplemented with: CaCl2.2H2O 1 mM; MgCl2.6H2O 1 mM; glucose 5.6 mM; human 
serum albumin (HSA) 30 µg/ml.   The pH of PBS buffers was titrated to 7.3.   
 
2.2 Preparation of compounds 
Aspirin, naproxen, diclofenac, ibuprofen, indomethacin, FR122047, celecoxib and 
wortmannin were prepared as stock solutions (10 mM) in ethanol and stored at ±20 °C 
in appropriate aliquots.  Stem Cell Factor (SCF) was prepared as a stock solution (100 
µg/ml) in water and stored frozen in small aliquots.  Monoclonal anti-human IgE 
antibody (2 mg/ml stock) was stored frozen over the long-term but a working stock 
was kept at 4 °C for up to a month. 
 
2.3 Lung tissue 
Lung tissue was obtained following surgery.  Seventy-seven lung preparations were 
used in this study, 42 preparations were derived from males and 35 from females.  
The age range of participants was 28 to 89 years with a median age of 72.  Informed 
written consent was obtained.  This study was approved by the National Research 
(WKLFV¶Service (REC reference: 15/NW/0657).  
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2.4 Cell isolation 
Mast cells were isolated from human lung tissue using methods described in detail 
elsewhere (Lewis et al., 2013).  Macroscopically normal tissue from resections was 
disrupted physically and enzymatically (collagenase Ia) to generate a mixed cell 
suspension of which 3 to 13% of the cells were mast cells.  Mast cells were visualized 
by microscopy using an alcian blue stain.  This method generated approximately 6 x 
105 mast cells per g of tissue.  Mast cells of enhanced purity (10 to 69% purity; median 
35%) were generated by flotation over discontinuous Percoll gradients (Weston et al., 
1997).   Mast cells were further purified using a MACS magnetic cell sorting system 
0LOWHQ\L%LRWHF6XUUH\8.DFFRUGLQJWRWKHPDQXIDFWXUHU¶VLQVWUXFWLRQVDQGDV
described in detail elsewhere (Havard et al., 2011). Mast cell purities using this 
method ranged from 88 to 98% (median 90%).  When longer term incubations (4 or 20 
h) were necessary, cells were reconstituted in RPMI-1640 buffer supplemented with 
penicillin (10 Units/ml), streptomycin (10 Pg/ml), gentamicin (50 Pg/ml) fungizone (1 
Pg/ml) and FBS (5%). 
 
2.5 Mediator release 
Mediator release experiments were performed essentially as described elsewhere 
(Lewis et al., 2013).  Experiments were performed in +PBS buffer. Mediator release 
was initiated either with a mouse anti-IgE or SCF.  Human lung mast cells express 
endogenous IgE so the cells are responsive to anti-IgE without the need for passive 
sensitization with exogenously added IgE (Lewis et al., 2017).  SCF was used in this 
study as a non-IgE-dependent activator that has previously been shown to be an 
effective driver of PGD2 generation from human lung mast cells (Lewis et al., 2013).  
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When COX inhibitors were used, the cells were incubated for 15 min with the inhibitor 
before challenge with stimulus.  Wortmannin, a PI3K inhibitor, was also included in 
certain experiments acting as a positive inhibitory control.  Histamine released into 
supernatants was measured using an automated fluorometric method (Ennis, 1991). 
Total histamine content was determined by lysing aliquots of the cells with perchloric 
acid at a final concentration of 1.6%.  Cells incubated in buffer alone served as a 
measure of spontaneous histamine release which ranged from 2 to 8% of the total 
histamine content.  Histamine release was thus expressed as a percentage of the total 
histamine content after subtracting the spontaneous histamine release.  PGD2 and cys-
LT content in the supernatants were determined using commercially available kits 
(Cayman Chemical Company, Ann Arbor, MI, USA). All experiments were performed 
in duplicate. 
 
2.6 RT-PCR  
RNA was extracted from purified mast cells using Tri-Reagent (1 ml).  In order to 
generate cDNA, samples were processed essentially as described (Kay et al., 2013).  
Amplification of cDNA was performed by PCR using a modification of the conditions 
and primer pairs for human COX-1 and COX-2 described elsewhere (Picado et al., 
1999).  The house-NHHSLQJJHQHȕ-actin, was also amplified.  Primers were 
synthesised by Sigma (Poole, UK).  PCR primers used in this study can be found in 
Table S1 (Supporting Information repository).  PCR products were sequenced in-house 
to ensure that correct amplification had taken place as described in more detail 
elsewhere (Kay et al., 2013). 
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2.7 Immunoblotting 
Cell extracts were prepared for use in immunoblotting using a lysis buffer (Tris 50 
mM; NaCl 150 mM; PMSF 50 µg/ml; SBTI 50 µg/ml; leupeptin 5 µg/ml; aprotinin 5 
µg/ml; Triton X-100 0.5%; pH 8.0) according to methods described elsewhere 
(Fruman et al., 1992).  Cell lysates were prepared for electrophoresis as described 
(Havard et al., 2011).  Samples were subjected to SDS-PAGE (Mini-Sub Cell GT 
System; Bio-Rad, Hemel Hempstead, UK) using either 10 or 12% gels and then the 
separated proteins transferred electrophoretically to nitrocellulose membranes.  
Membranes were probed with a goat polyclonal antibody to COX-2 followed by 
secondary antibody (donkey anti-goat IgG-HRP). The membrane was stripped (0.2 M 
NaOH, 15 min) and probed with a rabbit polyclonal antibody to actin followed by 
secondary antibody (goat anti-rabbit IgG-HRP).  The membrane was stripped again 
and probed with goat polyclonal antibody for COX-1 followed by secondary antibody 
(donkey anti-goat IgG-HRP). Using a similar approach, the expression of lipocalin-
type PGD synthase (L-PGDS) and haematopoeitic-type PGDS (H-PGDS) was also 
evaluated in mast cells.  Protein bands were visualised by the addition of enhanced 
chemiluminescence (ECL) reagents and signals detected on ECL film.  Membranes 
were visualized using a BioRad ChemiDoc imaging system (Bio-Rad, Watford, UK). 
 
2.8 Materials 
The following were purchased from the sources indicated; aspirin, collagenase, 
DNase, HSA, ibuprofen, indomethacin, Percoll (Sigma, Poole, UK); gentamicin, 
penicillin/streptomycin, fungizone, RPMI 1640 (Invitrogen, Paisley, UK); diclofenac, 
FR122047, naproxen (Cayman Chemical Company, Ann Arbor, MI, USA); 
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wortmannin (Calbiochem, Nottingham, UK); celecoxib (BioVision, Milpitas, CA, 
USA); anti-human IgE, clone HP6061 (Stratech Scientific Ltd, Newmarket, UK); 
SCF (Peprotech, Rocky Hill, NJ, USA); ECL reagents, nitrocellulose membranes (GE 
Healthcare Life Sciences, Little Chalfont, UK).  All primary and secondary antibodies 
were purchased from Santa Cruz Biotechnology (Heidelberg, Germany) with the 
exception of rabbit polyclonal antibody to actin (Sigma, Poole UK) and goat anti-
rabbit IgG-HRP (Dako/Agilent, Santa Clara, CA, USA).  All other reagents were 
from Sigma (Poole, UK). 
 
2.9 Data analysis 
Potencies (EC50) were determined by non-linear regression analysis (GraphPad Prism, 
version 5.0d).  Statistical significance was assessed utilising repeated measures 
ANOVA.  WKHQDSSURSULDWHSRVWKRFDQDO\VLVZDVSHUIRUPHGXVLQJ'XQQHWW¶VWHVW 
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3. Results 
3.1 Effects of COX inhibitors on PGD2 generation 
The effects of a range of commonly used NSAIDs on PGD2 generation from human 
lung mast cells were investigated. The concentration (1 µM) of NSAIDs used in these 
preliminary experiments was considered to be maximally effective based on previous 
studies (Mitchell et al., 1994; Cryer and Feldman, 1998; Chan et al., 1999; Warner et 
al., 1999). IgE-dependent PGD2 generation was inhibited effectively by naproxen, 
ibuprofen and diclofenac (Fig. 1A). These same inhibitors had no effect on either IgE-
dependent cys-LT generation (Fig. 1B) or histamine release (Fig. 1C). By contrast, in 
these same experiments, aspirin was an ineffective inhibitor of PGD2 generation, and 
also had no effect on either cys-LT generation or histamine release. Further studies 
demonstrated that a higher concentration (10 µM) of aspirin could inhibit PGD2 
generation (Table 1) but the inhibition was far from complete (~38% inhibition) 
unlike the alternative NSAIDs studied which essentially abolished PGD2 generation 
(Fig. 1A).   
3UHYLRXVFOLQLFDOVWXGLHV2¶6XOOLYDQHWDOCahill et al., 2015) and in 
vitro studies using peripheral blood derived mast cells (Steinke et al., 2014) suggest 
that aspirin may directly activate mast cells.  However, in this study, we were unable 
to demonstrate that aspirin or alternative NSAIDs were capable of inducing mediator 
release from human lung mast cells.  
In further studies the effects of FR122047 (COX-1 selective) and celecoxib 
(COX-2 selective) as well as the NSAID, indomethacin, on PGD2 generation from 
human lung mast cells were investigated. The PI3K inhibitor, wortmannin, was 
included in these experiments as a positive inhibitory control. Both indomethacin and 
FR122047 were effective inhibitors of PGD2 generation induced by anti-IgE whereas 
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celecoxib was ineffective (Fig. 2A). None of the COX inhibitors had much of an 
effect on the generation of cys-LTs (Fig. 2B) or release of histamine (Fig. 2C).  
Previous studies have demonstrated an increase in the mast cell growth factor, 
SCF, in asthma (Al-Muhsen et al., 2004; Kowalski et al., 2005; Da Siva et al., 2006).  
A recent study of ours has shown that SCF is also an effective driver of mediator 
release from human lung mast cells especially PGD2 generation (Lewis et al., 2013).  
The effects of FR122047 and celecoxib as well as indomethacin on PGD2 generation 
driven by SCF from human lung mast cells were investigated.  Both FR122047 and 
indomethacin were very effective inhibitors of PGD2 generation whereas celecoxib 
was ineffective (Fig. 3A).  None of the COX inhibitors had any effect on the SCF-
induced generation of cys-LTs (Fig. 3B) or release of histamine (Fig. 3C).  
Further studies were performed with FR122047 using an extended 
concentration range (10-11 ± 10-6 M).  FR122047 inhibited PGD2 generation by either 
anti-IgE or SCF in a concentration-dependent manner (Fig. 4). FR122407 was slightly 
more potent as an inhibitor of PGD2 generation induced by SCF than anti-IgE (EC50 
for FR122047 of 9 and 38 nM, respectively). 
 
3.2 Expression of COX isoforms by mast cells 
RT-PCR was performed in order to determine whether mast cells express message for 
COX-1 and/or COX-2 (Fig. 5). The data demonstrate that mast cells express mRNA 
for both COX-1 and COX-2. Further studies were performed to determine expression 
of COX-1 and COX-2 at the protein level. The data show that, overall, mast cells 
strongly express COX-1 and weakly express COX-2 (Fig. 6).   
 
3.3 Effects of longer-term activation of mast cells on PGD2 generation 
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In further studies, we investigated whether longer-term activation of mast cells 
influenced PGD2 generation.  Mast cells were activated with either anti-IgE or SCF 
for discrete time intervals (0.5 to 4 h) and PGD2 generation monitored. The data show 
that PGD2 generation showed no time-dependency when the cells were activated with 
anti-IgE (Fig. 7A) whereas when the cells were activated with SCF (Fig. 7B), 
significantly (P < 0.05) more PGD2 (more than twice as much) was generated at 4 h 
compared to 30 min.  
Experiments were then performed to determine whether this effect of SCF 
might be related to the up-regulation of COX isoforms. Treatment with SCF (4 or 20 
h) had no effect on the expression of either COX-1 or COX-2 (Fig. 8A, 8B).  We also 
investigated whether LPS was able to affect COX expression in mast cells since our 
own studies demonstrate that LPS is a strong inducer of COX-2 in lung macrophages 
(Fig S1, Supporting Information repository).  However our data show that LPS has no 
effect on COX expression in human lung mast cells (Fig. 8B). 
We also investigated whether mast cell activation might lead to up-regulation 
of PGDS expression by mast cells. Mast cells expressed haematopoeitic-type but not 
lipocalin-type PGDS, the latter synthase more usually associated with the central 
nervous system (Fig. 8C).  Following activation with SCF (4 or 20 h) or LPS (20 h) 
there was no increase in expression of either of these synthases (Fig. 8A, 8C). 
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4. Discussion 
In the present study, we have assessed the effects of a variety of COX inhibitors and 
investigated COX expression in human lung mast cells. Taken together, these studies 
indicate that COX-1 is the principal isoform responsible for PGD2 generation in these 
cells.  
Studies with COX-selective inhibitors were particularly informative.  That 
FR122047 abolished IgE-dependent PGD2 generation provided strong evidence that 
COX-1 is responsible for the production of PGD2 in human lung mast cells.  
FR122047 inhibits human recombinant COX-1 with an IC50 of ~30 nM and is about 
2000 fold more potent against COX-1 than COX-2 (Ochi et al., 2000). The potency of 
FR122047 (EC50 ~25 nM) as an inhibitor of PGD2 generation from human lung mast 
cells was very much in keeping with an effect at COX-1.  By contrast, that celecoxib 
was unable to inhibit PGD2 argues against a role for COX-2.  It should be noted that 
although celecoxib shows some modest selectivity for COX-2 over COX-1, it is 
possible that at higher concentrations, celecoxib may target COX-1 to some extent 
(Chan et al., 1999; Warner et al., 1999). Nonetheless, in the present study, celecoxib 
was ineffective.  Collectively, these data suggest that IgE-dependent PGD2 generation 
from human lung mast cells is driven by COX-1. 
In further studies, we investigated the effects of COX inhibitors on SCF driven 
PGD2 generation from mast cells. Elevated concentrations of the mast cell growth 
factor, SCF, have been observed in asthma (Al-Muhsen et al., 2004; Kowalski et al., 
2005; Da Silva et al., 2006) and our recent work has shown that SCF is unexpectedly 
effective at stimulating PGD2 generation from mast cells (Lewis et al., 2013).  
Previous studies have shown that mouse bone marrow derived mast cells express both 
COX-1 and COX-2 and that whereas IgE-dependent PGD2 generation mobilises 
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COX-1, cytokine driven PGD2 generation activates COX-2 (Murakami et al., 1995).  
However, in the present study, SCF-induced PGD2 generation was inhibited 
effectively by FR122047 whereas celecoxib was ineffective.  Overall, these findings 
suggest that COX-1 is the primary isoform that mediates both IgE- and SCF-
dependent PGD2 generation. These findings strongly support clinical studies showing 
that COX-1 is likely to be the main driver of PGD2 generation in asthma (Daham et 
al., 2011). 
 The effects of commonly used NSAIDs on PGD2 production from human lung 
mast cells were instructive inasmuch as these compounds are largely considered to be 
non-selective although data from a number of sources indicate some preference for 
either COX-1 or COX-2 (Mitchell et al., 1994; Cryer and Feldman, 1998; Chan et al., 
1999; Warner et al., 1999).  Selectivity for a given isoform may be dependent on the 
enzyme system studied.  Taking the literature collectively, indomethacin and aspirin 
appear to be predominantly COX-1 selective, diclofenac is somewhat COX-2 
selective, naproxen and ibuprofen overall display only fractional selectivity for one or 
other isoform.  It is of interest that all the NSAIDs studied inhibited PGD2 generation 
very effectively with the notable exception of aspirin which was a surprisingly weak 
inhibitor. The reasons for this are not really apparent.  If an assumption is made that 
COX-1 is the primary isoform present in mast cells then aspirin is at least as potent at 
COX-1 as some of the other NSAIDs studied such as ibuprofen yet ibuprofen was 
effective at blocking PGD2 generation.  Why aspirin was relatively ineffective is 
difficult to understand unless there are issues with aspirin accessing and/or 
inactivating mast cell COX.   
 Expression of COX isoforms was determined both by RT-PCR and by 
Western blotting.  Strong mRNA expression was observed for both COX-1 and COX-
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2.  However, at the protein level the picture was somewhat different and it was clearly 
evident that human lung mast cells strongly express COX-1 and only weakly express 
COX-2 in the majority of mast cell preparations.  These findings are at odds with 
studies in murine systems as well as cultured human mast cells wherein both COX-1 
and COX-2 are thought to co-exist (Murakami et al., 1995; Reddy et al., 1997; Obata 
et al., 1999).     
 Based on previous studies in a mouse mast cell line (Reddy et al., 1997), the 
possibility was considered that discrete COX isoforms might be mobilised in a time-
dependent fashion. Mast cells were activated for time intervals of 30 min to 4 h with 
either anti-IgE or SCF.  It was of interest that the extent of PGD2 generation induced 
by anti-IgE was the same after 30 min or 4 h whereas when SCF was used as a 
stimulus, over twice as much PGD2 was generated after 4 h compared to 30 min.  
These data suggested that SCF can drive PGD2 generation continuously over at least 4 
h.   
We considered whether this continuous release of PGD2 by SCF might be due 
to the induction of COX-2.  However, our data showed that COX-2 levels did not 
change following longer-term activation of mast cells with SCF.  In point of fact a 
well-recognised inducer of COX-2, LPS, was also investigated to determine whether 
this would induce COX-2 (Hempel et al., 1994).  However, LPS failed to induce up-
regulation of COX-2 in mast cells but readily did so in isolated human lung 
macrophages.  The possibility that SCF might induce PGDS was also considered but, 
similarly, there was no indication that SCF induced PGDS.  Presumably, the nature of 
the SCF/c-kit interaction transduces signals that permit continuous ongoing activation 
of the pathway leading to PGD2 generation.  
 17 
 In the clinical context, these studies may have some bearing on mechanistic 
aspects related to aspirin-intolerant asthma. Aspirin-intolerant asthma has been shown 
to be accompanied by increases in cys-LTs and PGD2 2¶6XOOLYDQHWDO&DKLOO
et al., 2015).  This association with PGD2 has led to suggestions that aspirin directly 
activates mast cells by an unidentified mechanism (Steinke et al., 2014). While the 
possibility exists that mast cells in asthmatic lung or discrete subsets of mast cells 
found in particular areas of the lung may behave differently in response to aspirin, we 
were unable to demonstrate that aspirin can activate human lung mast cells directly.   
Another mechanism that has been forwarded to explain some of the adverse 
effects of NSAIDs in respiratory conditions is that blocking COX can lead to 
increased availability of arachidonic acid for metabolism by the lipoxygenase 
pathway and thereby enhanced generation of cys-LTs (Hamad et al., 2004). Overall, 
data in the present study suggested that such a mechanism would be unlikely to occur 
(see Fig. 2B and Fig 3B).  One reason why a clear enhancement of cys-LT generation 
was not readily observed may have been related to the fact that, in these experiments, 
maximally effective concentrations of stimuli were used. It is possible therefore that if 
optimal levels of cys-LTs were already being generated by a stimulus then there may 
have been limited opportunity to see any enhancement with a COX inhibitor.  For this 
reason, additional experiments were performed utilising a submaximal concentration 
of anti-IgE (0.1 µg/ml), 20-fold lower than maximal, to determine whether selected 
COX inhibitors might enhance cys-LT generation from activated mast cells.  
Although there was some variability among experiments, overall there was no 
evidence for enhancement of cys-LTs by COX inhibitors under these conditions (see 
Fig S2, Supporting Information repository).  These data are not altogether unexpected 
since, in other systems, inhibition of COX does not promote increased conversion of 
 18 
DUDFKLGRQLFDFLGE\WKHOLSR[\JHQDVHSDWKZD\6XG¶LQDHWDOAlthough not 
explored in the present study, the possibility that arachidonic acid might also be 
converted to other active metabolites by alternative pathways cannot be excluded 
(Feltenmark et al., 2008; Wendell et al., 2014). 
An alternative possibility that has been put forward to explain aspirin-
intolerant asthma is that COX inhibition by aspirin may reduce PGE2.  Whereas in 
general PGE2 is known to have pro-inflammatory effects, paradoxically in the lung, 
PGE2 is a bronchodilator and inhibits human lung mast cells (Gauvreau et al., 1999; 
Hartert et al., 2000; Buckley et al., 2011; Kay et al., 2013). The loss of an endogenous 
stabiliser of mast cells in PGE2 could permit an increase in the release of mast cell 
derived mediators.  If, as we have shown in the present study, aspirin was also 
ineffective at inhibiting mast cell COX, this might then be reflected by even greater 
levels of PGD2 generation.  Thus an increased elaboration of PGD2 by aspirin may 
reflect an inability to contain PGD2 generation rather than direct activation of the mast 
cell.   
 In summary, we have shown that PGD2 generation by mast cells is driven by 
COX-1.  We have been unable to demonstrate any supporting role for COX-2.  While 
the possibility cannot be excluded that mast cells in different disease states may 
behave differently, our findings strongly support the notion that COX-1 is the 
principal isoform driving PGD2 from human lung mast cells. 
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Table 1 Effects of aspirin on mediator release from human lung mast cells 
 
Aspirin              PGD2              cys-LT        histamine release 
  (µM)           (ng/106 mast cells)      (ng/106 mast cells)                (%)  
     -   82 ± 25  85 ± 26  26 ± 8 
    1   72 ± 20  79 ± 28  25 ± 7 
   10   51 ± 23*  93 ± 29  24 ± 7 
 
Mast cells were incubated (15 min) without (-) or with aspirin before challenge for a 
further 25 min with anti-IgE for mediator release.  Values are means ± S.E.M., for 5 
different mast cell preparations.  Statistically significant reduction in PGD2 generation 
compared to control (-) is indicated, *P < 0.05 
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Figure Legends 
Fig. 1 Effects of NSAIDs on mediator release. Mast cells were incubated (15 min) 
without (-) or with either aspirin (ASP), naproxen (NAP), ibuprofen (IBU) or 
diclofenac (DIC) before challenge for a further 25 min with anti-IgE for mediator 
release.  Effects of NSAIDs on (A) PGD2, (B) cys-LT and (C) histamine generation 
were evaluated. Values are means ± S.E.M., for 4 different mast cell preparations.  
Statistically significant reductions in PGD2 generation compared to control (-) are 
indicated, *P < 0.05.  
 
Fig. 2 Effects of COX-selective inhibitors on IgE-dependent mediator release.  Mast 
cells were incubated (15 min) without (-) or with either indomethacin (IND), 
FR122047 (FR), celecoxib (CEL) or wortmannin (W) before challenge for a further 
25 min with anti-IgE (2 µg/ml) for mediator release.  Effects of NSAIDs on (A) 
PGD2, (B) cys-LT and (C) histamine generation were evaluated. Values are means ± 
S.E.M., for 4 different mast cell preparations.  Statistically significant alterations in 
mediator release generation compared to control are indicated, *P < 0.05. 
 
Fig. 3 Effects of COX-selective inhibitors on SCF-induced mediator release.  Mast 
cells were incubated (15 min) without (-) or with either indomethacin (IND), 
FR122047 (FR), celecoxib (CEL) or wortmannin (W) before challenge for a further 
25 min with SCF (100 ng/ml) for mediator release.  Effects of NSAIDs on (A) PGD2, 
(B) cys-LT and (C) histamine generation were evaluated. Values are means ± S.E.M., 
for 5 different mast cell preparations.  Statistically significant reductions in mediator 
release generation compared to control are indicated, *P < 0.05. 
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Fig. 4 Effect of FR122047 on PGD2 generation.  Mast cells were incubated without  
or with FR122047 for 15 min before challenge for a further 25 min with either anti-
IgE (2 µg/ml) or SCF (100 ng/ml) for PGD2 generation.  Results are expressed as the 
% inhibition by FR122047 of the control unblocked PGD2 generation which was 
191±30 ng of PGD2 per 106 mast cells for anti-IgE and 84±24 ng of PGD2 per 106 
mast cells for SCF. Values are means ± S.E.M., for 6 different mast cell preparations.   
 
Fig. 5 COX isoform expression in human lung mast cells.  Isolated RNA was 
converted to cDNA by reverse trancriptase (+) and this step was also carried out in the 
absence of reverse transcriptase for control purposes (-).  Amplification of cDNA was 
performed using primers for COX-1 and COX-2 and for ȕ-actin.  Expression profiles 
for 3 mast cell preparations (HLMC-1, HLMC-2 and HLMC-3) are shown. Data are 
representative of a total of 6 different mast cell preparations in excess of 95% purity.  
Lanes at either end of each gel represent molecular weight standards (mw) comprising 
a 100 bp ladder. 
 
Fig. 6 Immunoblot for COX isoform expression in human lung mast cells.  (A) Three 
mast cell preparations (HLMC-1, HLMC-2 and HLMC-3) were solubilized and 
subjected to SDS-PAGE along with a mixed lung cell (MLC) preparation.  Following 
electrophoretic transfer to a nitrocellulose membrane, the membrane was probed with 
an antibody to COX-2, the membrane stripped and probed with antibody to actin and 
the membrane stripped again and probed with antibody to COX-1. mw stands for 
molecular weight standards. (B) COX-1 and COX-2 content in mast cells was 
determined by densitometry.  Content is expressed relative to the same MLC 
preparation that was used as a control in all blots and normalised relative to cell actin.  
 30 
Open symbols represent the COX content in individual mast cell preparations, filled 
symbols the mean value. Data are for 13 different mast cell preparations.   
 
Fig. 7 Time-dependence of PGD2 generation.  Mast cells were incubated for between 
30 min to 4 h with either (A) anti-IgE (2 µg/ml) or (B) SCF (100 ng/ml) after which 
PGD2 generation was assessed. Values are means ± S.E.M., for 4 different mast cell 
preparations.  There was significantly greater generation of PGD2 after 4 h with SCF 
compared to a 30 min challenge, *P < 0.05.   
 
Fig. 8 Effects of LPS and SCF on COX and PGDS expression.  (A) Two mast cell 
preparations (HLMC-1 and HLMC-2) were incubated (4 h) without (-) or with SCF 
(100 ng/ml) and expression of COX-1, COX-2, H-PGDS and E-actin evaluated. A 
mixed lung cell (MLC) preparation was also included. (B) A single mast cell 
preparation was incubated (20 h) in buffer (-), LPS (100 ng/ml) or SCF (100 ng/ml) 
and expression of COX-1 and COX-2 evaluated.  An MLC preparation was also 
included. (C) A single mast cell preparation was incubated (20 h) in buffer (-), LPS 
(100 ng/ml) or SCF (100 ng/ml) and expression of H-PGDS and L-PGDS evaluated.  
A solubilized mouse brain preparation was also included as a control for L-PGDS.  
Experiments were performed 3 or more times for (A), (B) and (C).  mw stands for 
molecular weight standards. 
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Fig. 1 
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Fig. 3 
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